

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12383147
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Davies; Helen et al.

Apparatus and method of assessing a narrowing in a fluid filled tube

Abstract

An apparatus and method of assessing a narrowing in a fluid filled tube having a fluid flow pressure wave having a backward-originating pressure component and a forward-originating pressure component without taking a flow velocity measurement, comprising: taking pressure measurements in the tube; separating the pressure components into the backward-originating pressure component and the forward-originating pressure component; identifying a time window when the differential of flow velocity (dU) is minimal or absent; and deriving the backward and forward pressure components for pressure measurements taken in at least the time window.

Inventors: Davies; Helen (London, GB), Davies; Justin (London, GB)

Applicant: MEDSOLVE LTD. (London, GB); IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (South Kensington, GB)

Family ID: 43663843

Assignee: MEDSOLVE PTE LTD (London, GB); IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (London, GB)

Appl. No.: 17/867155

Filed: July 18, 2022

Prior Publication Data

Document Identifier	Publication Date
US 20220354370 A1	Nov. 10, 2022

Foreign Application Priority Data

GB	1100137	Jan. 06, 2011
----	---------	---------------

Related U.S. Application Data

continuation parent-doc US 16853523 20200420 US 11389068 child-doc US 17867155
continuation parent-doc US 15723182 20171003 US 10624544 20200421 child-doc US 16853523
continuation parent-doc US 14701000 20150430 US 9775524 20171003 child-doc US 15723182
continuation parent-doc US 13345495 20120106 US 9026384 20150505 child-doc US 14701000

Publication Classification

Int. Cl.: **G06F11/30** (20060101); **A61B5/00** (20060101); **A61B5/02** (20060101); **A61B5/021** (20060101); **A61B5/0215** (20060101); **A61B5/0285** (20060101); **A61B5/103** (20060101)

U.S. Cl.:

CPC **A61B5/02007** (20130101); **A61B5/02125** (20130101); **A61B5/0215** (20130101); **A61B5/0285** (20130101); **A61B5/103** (20130101); **A61B5/7264** (20130101); **A61B5/7278** (20130101);

Field of Classification Search

CPC: A61B (5/02007)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
4821735	12/1988	Goor	N/A	N/A
5775338	12/1997	Hastings	N/A	N/A
6062089	12/1999	Ichihashi	N/A	N/A
6106476	12/1999	Corl	N/A	N/A
6129674	12/1999	Ovadia-Blechman	N/A	N/A
6190355	12/2000	Hastings	N/A	N/A
6193669	12/2000	Degany	N/A	N/A
6343514	12/2001	Smith	N/A	N/A
6354999	12/2001	Dgany	N/A	N/A
6396615	12/2001	Hama	N/A	N/A
6409677	12/2001	Tulkki	N/A	N/A
6471656	12/2001	Shalman	N/A	N/A
6558334	12/2002	Shalman	N/A	N/A
6565514	12/2002	Svanerudh	N/A	N/A
6585660	12/2002	Dorando	N/A	N/A
6615667	12/2002	Smith	N/A	N/A
6659959	12/2002	Brockway	N/A	N/A
6663570	12/2002	Mott	N/A	N/A
6697667	12/2003	Lee	N/A	N/A
6716178	12/2003	Kilpatrick	N/A	N/A
6754608	12/2003	Svanerudh	N/A	N/A
6868736	12/2004	Sawatari	N/A	N/A
7134994	12/2005	Alpert	N/A	N/A
7274956	12/2006	Mott	N/A	N/A

RE39863	12/2006	Smith	N/A	N/A
7329223	12/2007	Ainsworth	N/A	N/A
7481774	12/2008	Brockway	N/A	N/A
7532920	12/2008	Ainsworth	N/A	N/A
7632304	12/2008	Park	N/A	N/A
7693563	12/2009	Suresh	N/A	N/A
7775988	12/2009	Pijs	N/A	N/A
7783338	12/2009	Ainsworth	N/A	N/A
7814635	12/2009	Gordon	N/A	N/A
7828841	12/2009	Mathis	N/A	N/A
7828842	12/2009	Nieminen	N/A	N/A
7828843	12/2009	Alferness	N/A	N/A
7853626	12/2009	Jung	N/A	N/A
7887582	12/2010	Mathis	N/A	N/A
8006594	12/2010	Hayner	N/A	N/A
8029447	12/2010	Kanz	N/A	N/A
8062358	12/2010	Mathis	N/A	N/A
8075608	12/2010	Gordon	N/A	N/A
8157742	12/2011	Taylor	N/A	N/A
9775524	12/2016	Davies	N/A	A61B 5/7278
10624544	12/2019	Davies	N/A	N/A
11389068	12/2021	Davies	N/A	A61B 5/7278
2002/0052553	12/2001	Shalman	N/A	N/A
2002/0059827	12/2001	Smith	N/A	N/A
2002/0065472	12/2001	Brockway	N/A	N/A
2002/0072880	12/2001	Svanerudh	N/A	N/A
2002/0173724	12/2001	Dorando	N/A	N/A
2003/0032886	12/2002	Deganv	N/A	N/A
2003/0033095	12/2002	Svanerudh	N/A	N/A
2003/0159518	12/2002	Sawatari	N/A	N/A
2003/0163052	12/2002	Mott	N/A	N/A
2003/0191400	12/2002	Shalman	N/A	N/A
2003/0195428	12/2002	Brockway	N/A	N/A
2003/0204160	12/2002	Kamm	604/8	G16H 50/50
2003/0216621	12/2002	Alpert	N/A	N/A
2004/0082866	12/2003	Mott	N/A	N/A
2004/0158321	12/2003	Reuter	N/A	N/A
2005/0121734	12/2004	Degertekin	N/A	N/A
2006/0052700	12/2005	Svanerdh	N/A	N/A
2006/0074318	12/2005	Ahmed	N/A	N/A
2006/0106321	12/2005	Lewinsky	N/A	N/A
2006/0241505	12/2005	Ahmed	N/A	N/A
2007/0060822	12/2006	Alpert	N/A	N/A
2007/0078352	12/2006	Pills	N/A	N/A
2007/0225606	12/2006	Naghavi	N/A	N/A
2007/0225614	12/2006	Naghavi	N/A	N/A
2007/0255145	12/2006	Smith	N/A	N/A
2008/0027330	12/2007	Naghavi	N/A	N/A
2008/0081957	12/2007	Jung	N/A	N/A
2008/0082522	12/2007	Jung	N/A	N/A

2008/0082582	12/2007	Jung	N/A	N/A
2008/0101532	12/2007	Tkaczyk	N/A	N/A
2008/0139951	12/2007	Patangay	N/A	N/A
2008/0213165	12/2007	Lieu	N/A	N/A
2008/0228086	12/2007	Johnson	N/A	N/A
2008/0255471	12/2007	Naghavi	N/A	N/A
2008/0269572	12/2007	Kanz	N/A	N/A
2008/0281205	12/2007	Haghavi	N/A	N/A
2008/0292049	12/2007	Camus	N/A	N/A
2009/0018459	12/2008	Tseng	N/A	N/A
2009/0081120	12/2008	Lieu	N/A	N/A
2009/0082678	12/2008	Smith	N/A	N/A
2009/0088650	12/2008	Corl	N/A	N/A
2009/0234231	12/2008	Knight	N/A	N/A
2010/0081941	12/2009	Naghavi	N/A	N/A
2010/0086483	12/2009	Belardinelli	N/A	N/A
2010/0109104	12/2009	Tiensuu	N/A	N/A
2010/0152607	12/2009	Kassab	N/A	N/A
2010/0156898	12/2009	Voros	N/A	N/A
2010/0234698	12/2009	Manstrom	600/478	A61M 25/09
2010/0241008	12/2009	Belleville	N/A	N/A
2010/0280396	12/2009	Zhang	N/A	N/A
2010/0286537	12/2009	Pills	N/A	N/A
2011/0066047	12/2010	Belleville	N/A	N/A
2011/0071404	12/2010	Schmitt	N/A	N/A
2011/0071407	12/2010	Hubinette	N/A	N/A
2011/0085977	12/2010	Rosenmeier	N/A	N/A
2011/0137140	12/2010	Tearney	N/A	N/A
2011/0137210	12/2010	Johnson	N/A	N/A
2011/0178383	12/2010	Kassab	N/A	N/A
2011/0178413	12/2010	Schmitt	N/A	N/A
2011/0178417	12/2010	Kassab	N/A	N/A
2011/0196255	12/2010	Kassab	N/A	N/A
2011/0245693	12/2010	Hastings	N/A	N/A
2011/0251497	12/2010	Corl	N/A	N/A
2011/0263986	12/2010	Park	N/A	N/A
2011/0306867	12/2010	Gopinathan	N/A	N/A
2011/0319752	12/2010	Steinberg	N/A	N/A
2011/0319773	12/2010	Kanz	N/A	N/A
2012/0004529	12/2011	Tolkowsky	N/A	N/A
2012/0004537	12/2011	Tolkowsky	N/A	N/A
2012/0029339	12/2011	Cohen	N/A	N/A
2012/0041318	12/2011	Taylor	N/A	N/A
2012/0041319	12/2011	Taylor	N/A	N/A
2012/0041320	12/2011	Taylor	N/A	N/A
2012/0041321	12/2011	Taylor	N/A	N/A
2012/0041322	12/2011	Taylor	N/A	N/A
2012/0041323	12/2011	Taylor	N/A	N/A
2012/0041324	12/2011	Taylor	N/A	N/A
2012/0041735	12/2011	Taylor	N/A	N/A

2012/0041739	12/2011	Taylor	N/A	N/A
2012/0052918	12/2011	Taylor	N/A	N/A
2012/0053918	12/2011	Taylor	N/A	N/A
2012/0053919	12/2011	Taylor	N/A	N/A
2012/0053921	12/2011	Taylor	N/A	N/A
2012/0059246	12/2011	Taylor	N/A	N/A
2012/0065514	12/2011	Naghavi	N/A	N/A
2012/0065623	12/2011	Nelson	N/A	N/A
2012/0071782	12/2011	Patil	N/A	N/A
2012/0072190	12/2011	Sharma	N/A	N/A
2012/0093266	12/2011	Sun	N/A	N/A
2012/0101355	12/2011	Gopinathan	N/A	N/A
2012/0101369	12/2011	Patil	N/A	N/A
2012/0220883	12/2011	Manstrom	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2298162	12/2010	EP	N/A
3120762	12/2016	EP	N/A
200053081	12/1999	WO	N/A
2006041346	12/2005	WO	N/A
2012030882	12/2009	WO	N/A
2010103277	12/2009	WO	N/A
200113779	12/2010	WO	N/A
2011038044	12/2010	WO	N/A
20120093266	12/2011	WO	N/A

OTHER PUBLICATIONS

A.W. Khir et al., "Determination of Wave Speed and Wave Separation in the Arteries," Journal of Biomechanics, vol. 34, No. 9, pp. 1145-1155, Sep. 30, 2001. cited by applicant

Justin E. Davies et al., "Evidence of Dominant backward-Propagating 'Suction' Wave Responsible for Diastolic Coronary Filling in Humans, Attenuated in Left Ventricular Hypertrophy," American Heart Association, vol. 113, No. 14, Apr. 11, 2006, pp. 1768-1778. cited by applicant

Jazmin Aguado-Sierra et al., "Pressure Reservoir-Wave Separation Applied to Coronary Arterial Data," 29th IEEE EMBS Annual International Conference, Dec. 31, 2007, pp. 2693-2696. cited by applicant

The State Intellectual Property Office of the People's Republic of China, "Notification of First Office Action" for Application No. 201280004879.6, mailed Feb. 10, 2015, 22 pages with translation. cited by applicant

Canadian Intellectual Property Office, "Office Action" for Application No. 2,823,811, mailed Sep. 11, 2015, 3 pages. cited by applicant

Japanese Patent Office, "Notice of Reasons for Refusal" for Application No. 2013-547911, mailed Oct. 6, 2015, 11 pages with translation. cited by applicant

The State Intellectual Property Office of the People's Republic of China, "Notification of Second Office Action" for Application No. 201280004879.6, mailed Nov. 4, 2015, 15 pages with translation. cited by applicant

Russian Patent Office, "Office Action" for Application No. 2013136699, mailed Dec. 10, 2015, 6 pages with translation. cited by applicant

European Patent Office, "Examination Report" for Application No. 12700299.6, mailed Jan. 18, 2016, 4 pages. cited by applicant

Chinese State Intellectual Property Office, “Notification of Third Office Action” for Application No. 201280004879.6, mailed May 9, 2016, 10 pages with translation. cited by applicant

International Searching Authority/European Patent Office, “International Search Report and The Written Opinion of the International Searching Authority,” for PCT/GB2012/050024, mailed Apr. 19, 2012, 14 pages. cited by applicant

Korean Office Action mailed Aug. 21, 2014 in Korean Patent Application No. 2013-7020712, filed Jan. 6, 2012. cited by applicant

European Patent Office, “Examination Report” for Application No. 12700299.6, mailed Aug. 31, 2016, 3 pages. cited by applicant

Canadian Office Action mailed Oct. 3, 2016 in Canadian Application No. T8477383CA—filed Oct. 3, 2016, 2 pages. cited by applicant

Japanese Patent Office, Office Action for Application No. 2013-547911, mailed Jul. 19, 2016, 7 pages with translation. cited by applicant

Israeli Patent Office, Office Action for Application No. 227351, mailed Aug. 23, 2016, 2 pages. cited by applicant

Chinese State Intellectual Property Office, “Notification of the Fourth Office Action” for Application No. 201280004879.6, mailed Jan. 20, 2017, 6 pages with translation. cited by applicant

SmartFlow tm Integrated Lumen Physiology, Version 5.0, Operator's Manual, Apr. 2001, 42 pages. cited by applicant

Florence Medical Innovations in Vascular Technology Business Plan, May 2002, 41 pages. cited by applicant

Florence Medical SmartFlow, CFR/FFR Manual, Mar. 2002, 50 pages. cited by applicant

SmartFlow CFR/FFR, Innovations in Vascular Technology, Model 2000, 2002, 6 pages. cited by applicant

Florence Medical, Annual Letter to Shareholders, May 17, 2001, 1 page. cited by applicant

Florence Medical LTD, Company Profile, May 2001, 4 pages. cited by applicant

SmartFlow tm Integrated Lumen Physiology for the Cathlab, SmartFlow CFR/FFR, Model 2000, Version 5.0 CFR/FFR, 2001, 2 pages. cited by applicant

Florence Medical Center 510(k) Summary SmartFlowtm, May 14, 2001, 6 pages and Oct. 2, 2001, 5 pages. cited by applicant

EuroPCR Brochure—SmartFlowTm Integrated Lumen Physiology, “Software Design Description” (4 parts)—Apr. 30, 2013. cited by applicant

Florence Medical, Inc. News Release, Florence Medical Introduces SmartFlow Multiple Lesion tm Device at American College of Cardiology Meeting, Mar. 14, 2002, 2 pages. cited by applicant

The Free Library by Farlex, Florence Medical Introduces SmartFlow Multiple Lesion Device at American College of Cardiology Meeting, Mar. 14, 2002, 3 pages. cited by applicant

Florence Medical innovations in vascular technology PowerPoint presentation, 2002, 19 pages. cited by applicant

Shalman, E., et al., Pergamon, Numerical modeling of the flow in stenosed coronary artery. The relationship between main hemodynamic parameters, Received Nov. 3, 2000, accepted Oct. 2, 2001, 16 pages. cited by applicant

Shalman, E., et al., Pergamon, Pressure-based simultaneous CFR and FFR measurements: understanding the physiology of a stenosed vessel, Received Jul. 18, 2000, accepted Oct. 6, 2000, 11 pages. cited by applicant

Grubert, Luis, M.D., et al., Simultaneous Assessment of Coronary Flow Reserve and Fractional Flow Reserve with a Novel Pressure-Based Method, Journal of Interventional Cardiology vol. 13, No. 5, 2000, 8 pages. cited by applicant

Young, D.F., et al., Pressure Drop Across Artificially Induced Stenoses in the Femoral Arteries of Dogs, Circulation Research, 1975; 36: 735-743. cited by applicant

The International Bureau of WIPO, Notification Concerning Submission, Obtention or Transmittal

of Priority Document for International Application No. PCT/GB2012/050024, dated Feb. 16, 2012, 1 page. cited by applicant

European Patent Office, The International Searching Authority, Notification of Transmittal of The International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/GB2012/050024, dated Apr. 19, 2012, 16 pages. cited by applicant

International Search Report and Written Opinion received in Patent Cooperation Treaty Application No. PCT/ JS2012/051566, dated Mar. 29, 2013, 9 pages. cited by applicant

International Search Report and Written Opinion received in Patent Cooperation Treaty Application No. PCT/ US2013/057647, dated Dec. 12, 2013, 11 pages. cited by applicant

Patent Cooperation Treaty, “International Preliminary Report on Patentability,” for Application No. PCT/ JS2013/057647, Mar. 12, 2015, 7 pages. cited by applicant

European Patent Office, “European Search Report” for Application No. 12825326.7, (PCT/U.S. Pat. No. 2012051566), Mar. 16, 2015, 7 pages. cited by applicant

European Patent Office, “European Search Report” for Application No. 12826470.2, (PCT/U.S. Pat. No. 2012051570), Mar. 16, 2015, 8 pages. cited by applicant

Russian Patent Office, “Office Action” for Application No. 2014110701, May 4, 2016, 17 pages with English translation. cited by applicant

Russian Patent Office, “Office Action” for Application No. 2014110702, May 4, 2016, 14 pages with English translation. cited by applicant

Pijls et al., The Crux of Maximum Hyperemia, The American College of Cardiology Foundation, Elsevier Inc., vol. 4, No. 10, 2011, pp. 1093-1095. cited by applicant

Khashaba et al., Intracoronary Versus Intravenous Adenosine-Induced Maximal Coronary Hyperemia for Fractional Flow Reserve Measurements, Clinical Medicine Insights: Cardiology, Libertas Academica 2014:8, pp. 17-21. cited by applicant

Schlundt et al., Comparison of Intracoronary Versus Intravenous Administration of Adenosine for Measurement of Coronary Fractional Flow Reserve, Circ Cardiovasc Interv, American Heart Association, Inc., 2015, pp. 1-7. cited by applicant

European Patent Office, “Extended European Search Report” for Application No. 16188188.3, Jan. 3, 2017, 10 pages. cited by applicant

Mynard JP et al: “Accurate Automatic Detection of End-Diastole From Left Ventricular Pressure Using Peak Curvature”, IEEE Transactions on Biomedical Engineering, Nov. 1, 2008, 7 pages. cited by applicant

Javier Escaned, et al., Importance of diastolic fractional flow reserve and dobutamine challenge in physiologic assessment of myocardial bridging, Journal of the American College of Cardiology, vol. 42, pp. 226-233, published Jul. 16, 2003. cited by applicant

Masayuki Abe, et al., Diastolic fractional flow reserve to assess the functional severity of moderate coronary artery stenoses, Circulation, vol. 102, pp. 2365-2370, published Nov. 7, 2000. cited by applicant

Mamas A. Mamas, et al., Resting Pd/Pa measured with intracoronary pressure wire strongly predicts fractional flow reserve, The Journal of Invasive Cardiology, vol. 22, pp. 260-265, published May 2010. cited by applicant

Primary Examiner: Huynh; Phuong

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATION (1) This application a continuation of U.S. application Ser. No. 16/853,523, filed Apr. 20, 2020, now U.S. Pat. No. 11,389,068, which is a continuation of U.S. application Ser. No. 15/723,182, filed Oct. 3, 2017, now U.S. Pat. No. 10,624,544, which is a continuation of U.S. application Ser. No. 14/701,000, filed Apr. 30, 2015, now U.S. Pat. No. 9,775,524, which is a continuation of U.S. application Ser. No. 13/345,495, filed Jan. 6, 2012, now U.S. Pat. No. 9,026,384, which claims priority to United Kingdom Patent Application No. GB1100137.7, filed Jan. 6, 2011, the disclosures of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

(1) This invention relates to an apparatus and method of assessing a narrowing in a fluid filled tube.

BACKGROUND TO THE INVENTION

(2) A fluid filled tube or vessel formed with a constriction or narrowing can be analysed to measure the magnitude of the constriction or narrowing.

(3) An example of a fluid filled tube or vessel formed with a constriction or narrowing is a blood vessel having a stenosis. Assessment or measurement of the constriction can result in a useful parameter to gauge the extent of the constriction.

(4) A standard methodology for assessment of a constriction in a fluid filled tube such as a coronary stenosis is fractional flow reserve (FFR). This technique measures the drop in pressure at two points along a vessel; see FIG. 1 of the accompanying drawings, under conditions of maximal achievable hyperaemia in a coronary environment. The Pd measurement comes from a pressure sensor on the wire and the Pa measurement comes from the catheter. A comparison is then made by expressing the mean distal pressure (Pd), as a proportion of mean proximal pressure (Pa), wherein the values are mean Pa and Pd over the entire cardiac cycle, taken over at least one complete cardiac cycle (but usually an average of 3 or more beats):

(5) $\text{FractionalFlowReserve(FFR)} = \frac{P_d}{P_a}$

(6) Conditions of maximal hyperaemia are usually only achievable by administration of potent vasodilators such as adenosine or dipyridamole. Such vasodilators are necessary to minimise resistance from the distal vascular bed to accurately estimate the drop in pressure across a stenosis. It would be preferable not to have to use vasodilators.

(7) Distal pressure arises from resistance of the microcirculation, in addition to active compression of small microcirculatory vessels which permeate the myocardium. When flow is measured simultaneously at different sites, it is possible to separate the pressure components arising from the distal myocardium (backward-originating pressure), from those arising from the proximal end (forward-originating pressure),

$$\begin{aligned} dP_+ &= \frac{1}{2(dP + \frac{1}{c}dU)} \\ (8) \quad dP_- &= \frac{1}{2(dP - \frac{1}{c}dU)} \end{aligned}$$

(9) where dP is the differential of pressure, ρ =density of blood, c=wave speed, and dU is the differential of flow velocity.

(10) P.sub.+ isolates forward originating pressure by removing the backward-originating component, and therefore negates the need for administration of vasoactive agents such as adenosine. Thus by comparing the ratio of P.sub.+ on either side of a stenosis it is possible to estimate stenosis severity without requiring maximal hyperaemia to be achieved. The isolated forward pressure ratio is expressed as:

$$(11) \text{Forwardpressure ratio} = \frac{P_{+distal}}{P_{+proximal}}$$

(12) Whilst the forward pressure ratio offers a considerable step forward as administration of vasodilator compounds are not required, it requires flow velocity to be measured in addition to pressure. This requires considerable extra skill, additional hardware and added expense.

- (13) It is an object of the invention to provide an apparatus and method of assessing a narrowing in a fluid filled tube which does not require a measurement of flow velocity, fluid flow rate, in addition to pressure measurement.
- (14) One aspect of the present invention provides a method of assessing a narrowing in a fluid filled tube having a fluid flow pressure wave having a backward-originating pressure component and a forward-originating pressure component without taking a flow velocity measurement, comprising: taking pressure measurements in the tube; separating the pressure components into the backward-originating pressure component and the forward-originating pressure component; identifying a time window when the differential of flow velocity (dU) is minimal or absent; and deriving the backward and forward pressure components for pressure measurements taken in at least the time window.
- (15) Another aspect of the present invention provides an apparatus to assess a narrowing in a fluid filled tube having a fluid flow pressure wave having a backward-originating pressure component and a forward-originating pressure component without taking a flow velocity measurement, the apparatus comprising: a pressure measurement device operable to take pressure measurements in the tube; and a processor operable to separate the pressure components into the backward-originating pressure component and the forward-originating pressure component; identify a time window when the differential of flow velocity (dU) is minimal or absent; and to derive the backward and forward pressure components for pressure measurements taken in at least the time window.
- (16) A further aspect of the present invention provides a processor configured to assess a narrowing in a fluid filled tube having a fluid flow pressure wave having a backward-originating pressure component and a forward-originating pressure component without taking a flow velocity measurement, the processor: analysing pressure measurements taken in a tube; separating the pressure components into the backward-originating pressure component and the forward-originating pressure component; identifying a time window when the differential of flow velocity (dU) is minimal or absent; and deriving the backward and forward pressure components for pressure measurements taken in at least the time window.
- (17) A yet further aspect of the present invention provides a data storage medium carrying a computer program to assess a narrowing in a fluid filled tube having a fluid flow pressure wave having a backward-originating pressure component and a forward-originating pressure component without taking a flow velocity measurement, the program: analysing pressure measurements taken in a tube; separating the pressure components into the backward-originating pressure component and the forward-originating pressure component; identifying a time window when the differential of flow velocity (dU) is minimal or absent; and deriving the backward and forward pressure components for pressure measurements taken in at least the time window.
-

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) In order that the present invention may be more readily understood, embodiments of the invention will now be described with reference to the accompanying drawings, in which:
- (2) FIG. 1 is a schematic diagram of a tube formed with a constriction with proximal (P_a) and distal (P_d) pressure measurement sites;
- (3) FIG. 2 is a schematic not-to-scale diagram of an apparatus embodying the present invention;
- (4) FIG. 3 is a flow diagram illustrating a method embodying the present invention;
- (5) FIG. 4 shows an example of a free wave period in a cardiac environment, which free wave period is used in an apparatus and method embodying the present invention.

DESCRIPTION

(6) This invention provides an apparatus and method of assessing a narrowing in a fluid filled tube by measuring the pressure in the tube and does not require a measurement of flow velocity, fluid flow rate, in addition to the pressure measurement.

(7) In a fluid flow system, the separated pressures are given as

$$(8) \quad dP_+ = \frac{1}{2(dP + \rho c dU)}$$
$$dP_- = \frac{1}{2(dP - \rho c dU)}$$

(9) where dP is the differential of pressure, ρ =density of blood, c =wave speed, and dU is the differential of flow velocity. The isolated pressure ratio, comparing the ratio of $P_{sub.+}$ or $P_{sub.-}$ on either side of a constriction provides a measure, estimate or indication of the severity of the constriction.

(10) The isolated forward pressure ratio using separated pressures is thus:

$$(11) \quad \frac{P_{+distal}}{P_{+proximal}}$$

(12) Or isolated backward pressure ratio,

$$(13) \quad \frac{P_{-distal}}{P_{-proximal}}$$

(14) Calculating the isolated pressure ratio using this technique gives a pressure only assessment of the severity of the constriction.

(15) Referring to FIG. 2, an apparatus 1 embodying the invention comprises a probe 2 such as an intra-arterial pressure wire (WaveWire or Combowire (Volcano Corp.) or Radi pressure wire (St Jude Medical) with a pressure measurement transducer 3—i.e. a device measuring pressure (P), and a processor 4 to analyse and operate on the pressure measurements. A signal line 5 relays the pressure measurement signal from the transducer 3 to the processor 4. The signal line 5 is illustrated both as a wired connection 5 and as a wireless connection 5'—either configuration is available.

(16) The processor 4 operates on the pressure measurements received from the transducer 3 in accordance with a number of algorithms which are discussed in greater detail below. The apparatus 1 may be provided in the following configurations or combination of configurations, but these are not an exhaustive list of configurations: a stand-alone device incorporating a probe with pressure measurement capacity in wired connection with a processor to provide on-device analysis; i) a device incorporating a probe with pressure measurement capacity in wireless connection with a processor to provide analysis at the processor; ii) a stand-alone device incorporating a probe with pressure measurement capacity and a data storage device operable to record measurement data for real time or subsequent communication to a processor to provide analysis at the processor (real time and/or off-line); and iii) a device incorporating a probe with pressure measurement capacity in wireless connection with a data storage device operable to record measurement data for real time or subsequent communication to a processor to provide analysis at the processor (real time and/or off-line).

(17) In the cardiac environment where the apparatus 1 is configured as part of haemodynamic equipment, the apparatus is configured using the processor 4 in the haemodynamic equipment, such as in McKesson equipment—Horizon Cardiology™, a cardiovascular information system (CVIS). Such configurations are particularly effective for the equipment processor to perform off-line analysis of the pressure data.

(18) The apparatus 1 (and in particular the probe 2) can be used in combination with other haemodynamic equipment, medical imaging equipment and/or in-patient marker location equipment.

(19) In a cyclic fluid flow system, there are time windows in which the rate of change of the fluid flow velocity tends to zero—i.e. dU tends to zero. At these times, termed here “wave free periods”, it is possible to separate the wave pressure in the fluid at a measurement site into forward and backward pressures using the pressure waveform alone. This negates the need for measurement of

flow velocity.

(20) In a specific example of a cardiac cycle, at any point in the cardiac cycle $dP_{sub,+}$ is determined by $dP + \rho c dU$. dU is large during parts of the cardiac cycle when significant proportions of wave energy are present (i.e. during left ventricular contraction). However, there are times in the cardiac cycle when dU tends to zero. This can be a single moment or sample in time, or a multiple moments or samples in time. At such times, the dU term can be cancelled and $dP_{sub,+}$ or $dP_{sub,-}$ estimated using the dP term alone.

(21) In accordance with this example of the invention, pressure samples are taken at or over the wave free period when dU tends to zero. Precise adherence to pressure sampling at or over the wave free period is not essential but pressure sampling does need to take place when the influence of dU is minimised and preferably when tending to zero.

(22) At or over the wave free period when the influence of dU is minimised or negated entirely, the dU side is cancelled from the separated pressures so:

(23) $dP_{sub,+}$ is calculated as

$$(24) dP_+ = \frac{1}{2(dP + \rho c dU)}$$

(25) and $dP_{sub,-}$ is calculated as

$$(26) dP_- = \frac{1}{2(dP - \rho c dU)}$$

(27) With the dU term cancelled) the separated pressures are calculated as:

$$dP_+ = \frac{1}{2}dP$$

(28) and

$$dP_- = \frac{1}{2}dP$$

(29) When dU tends to zero, the dU side is cancelled from the solution and $dP_{sub,+}$ is calculated as:

$$(30) dP_+ = \frac{1}{2}dP$$

and $dP_{sub,-}$ as,

$$(31) dP_- = \frac{1}{2}dP$$

(32) The apparatus and method provide for the separation of the wave pressure in the fluid at a measurement site into forward and backward pressures using the pressure waveform alone dispensing with the need for any measurement of flow velocity. This advance allows use of technically simplified equipment which does not need to measure fluid flow velocity.

(33) In the apparatus and method embodying the invention, the pressure measurements are made at baseline during the free wave period and not during hyperaemia. This is contrary to the teaching of FFR measurement in combined flow rate and pressure measurement apparatus where measurements are specifically taken at hyperaemia. This is because examples of the invention extract the forward pressure component, rather than (as in conventional FFR) having to minimise the contribution of backward pressure from the measured pressure by administration of vasodilators. If measurements are made during vasodilator hyperaemia, then measurements will not be reliable as dU increases significantly at this time.

(34) FIG. 4 shows an example of dU fluctuating over a cycle. There is an identifiable window where dU tends to zero (marked at 580 ms through to 770 ms in this example). The window is identified for example by being: heuristically learnt by the processor; linked to characteristics of the pressure waveform; or a certain time window after another event in the waveform e.g. starting at a predetermined time (250 ms) after event of $dU_{sub,max}$ and lasting for a predetermined period (150 ms)—note $dU_{sub,max}$ can be reliably observed from pressure measurements of the waveform. The wave free period is identifiable using online analysis in real time or can be identified using offline analysis

(35) For example, in a cardiac environment, detecting minimised dU (wave free period) from pressure measurements can be carried out as follows:

(36) identify peak pressure time ($t_{sub,Pmax}$)

- (37) identify end of pressure waveform time (t.sub.Pend)
- (38) sample pressure measurements from t.sub.Pmax to t.sub.Pend
- (39) analyse pressure measurements from (t.sub.Pmax+150 ms) through to (t.sub.Pend-50 ms)=wave free period.
- (40) Another example for identifying the wave free period is to base its identification on characteristics of the pressure waveform. This is advantageous because identification is not tied to fixed time points. In this specific example: calculate the isolated forward (or backward) pressure ratio; calculate standard deviation of isolated forward (or backward) pressure ratio select the time period (free wave period) after peak pressure time point where the standard deviation is in the lowest 5% and if no points are identified, select the time period where the standard deviation is in the lowest 10% and so on.
- The measurements are continuous within the identified free wave period and/or for a period of at least ~ 100 ms.
- (41) Another example for identifying the free wave period is:
- (42) identify the peak pressure time point;
- (43) identify the end of the pressure waveform time point; and
- (44) specifying the free wave period as a predetermined portion mid-window between these two time points. Preferably, the free wave period is identified as the mid 3/5 window between these two time points.
- (45) In the cardiac environment, reliable measurements are taken in the window where dU varies less than $\pm 2 \times 10^{-4}$ from the zero crossing, where dU.sub.max is 3×10^{-3} , where dU is 20% or less of dU.sub.max, preferably 10% or less, most preferably 5% or less. dU oscillates around the mean over the wave free period so its net contribution to separated pressures (i.e. P.sub.+) is minimised as the -ve contributions cancel the +ve contributions. The oscillations about the mean during the wave free period (the time window) in a cardiac environment are due to limitations in the measurement equipment which will not detect small changes accurately.
- (46) Further this advance provides a measure of the severity of a constriction using the measure of isolated pressure ratio.
- (47) Further this advance negates the need in the cardiac environment for the administration of potent vasodilators.
- (48) There are particular needs in the cardiac environment for simplified equipment having the smallest possible footprint (or being the least invasive requiring the smallest possible entry site) so the provision of an isolated pressure ratio measurement device or probe which has only one measurement device mounted on or in the probe represents a significant technical advance in that field.
- (49) Further, such devices or probes in the cardiac field include signal lines from the probe which terminate either in a transmitter for relaying the measurement signal to a processor or a processor itself. If there is a flow sensor and a pressure sensor, then two different measurement devices are in/on the same probe and there are also two signal lines required to take the signal from the two distinct measurement devices. The loss, in examples of the invention, of the flow sensor from the system is extremely beneficial as it reduces the complexity of the device, can improve handling of the probe and can reduce the number of signal lines necessary to take the measurement signal(s) away from the measurement devices. In the case of examples of the invention, there is only one measurement device—that of pressure measurement and the need for a flow sensor in addition to one or more pressure sensors is obviated. A single pressure sensor wire can be more manoeuvrable than a wire with both pressure and flow sensors. Having a flow sensor in addition to the pressure sensor is sub-optimal for guide wire design
- (50) Pressure-only measurements are taken relative to the constriction. Multiple measurements can be taken in preference to one measurement. The probe 2 can be moved relative to the constriction, in which case, multiple measurements would be taken.

(51) There is a further sophistication to the above described apparatus and method which concerns the identification of wave free periods—those times in the cyclic flow when dU tends to zero. A person skilled in the art is able to calculate and identify wave free periods—occurring as they do during periods of the cardiac cycle when wave activity is minimised or absent.

(52) For a given wave free period from time point two to time point $tw_{sub.1}$: with $P_{sub.+}$ (during any wave free period $tw_{sub.0}$ to $tw_{sub.1}$) as,

$$P_{sub.+} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.+}$$

and $P_{sub.-}$ as,

$$P_{sub.-} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.-}$$

where $P_{sub.+proximal}$ is defined as,

$$P_{sub.+proximal} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.+proximal}$$

and $P_{sub.+distal}$ is defined as,

$$P_{sub.+distal} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.+distal}$$

and $P_{sub.-proximal}$ is defined as,

$$P_{sub.-proximal} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.-proximal}$$

and $P_{sub.-distal}$ is defined as,

$$P_{sub.-distal} = \int_{tw_{sub.0}}^{tw_{sub.1}} dP_{sub.-distal}$$

(53) The isolated pressure ratio using separated pressures is thus isolated forward pressure:

$$(54) \frac{P_{+distal}}{P_{+proximal}}$$

(55) Or isolated backward pressure,

$$(56) \frac{P_{-distal}}{P_{-proximal}}$$

(57) Calculating the isolated pressure ratio using this technique over the wave free period gives a pressure-only assessment of the severity of the constriction, such as a stenosis. There is no need to provide flow velocity measurement equipment on the probe **2** in addition to the pressure measurement transducer **3** and there is no need to process any flow velocity measurement.

(58) When used in this specification and claims, the terms “comprises” and “comprising” and variations thereof mean that the specified features, steps or integers are included. The terms are not to be interpreted to exclude the presence of other features, steps or components.

(59) The features disclosed in the foregoing description, or the following claims, or the accompanying drawings, expressed in their specific forms or in terms of a means for performing the disclosed function, or a method or process for attaining the disclosed result, as appropriate, may, separately, or in any combination of such features, be utilised for realising the invention in diverse forms thereof.

Claims

1. A system of assessing a narrowing in a blood vessel, the system comprising: at least one pressure-sensing probe sized and shaped for positioning within the blood vessel; and a processor in communication with the at least one pressure-sensing probe, the processor configured to: receive pressure measurements occurring during a cardiac cycle without hyperaemia obtained by the at least one pressure-sensing probe positioned within the blood vessel; and calculate a pressure ratio using a subset of the pressure measurements occurring during a wave free period of the cardiac cycle, wherein the pressure ratio provides an assessment of a severity of the narrowing in the blood vessel.
2. The system of claim 1, wherein a start of the wave free period occurs after a first characteristic of a pressure waveform of the received pressure measurements.
3. The system of claim 2, wherein the first characteristic of the pressure waveform is a peak pressure.
4. The system of claim 2, wherein an end of the wave free period occurs before a second

characteristic of the pressure waveform of the received pressure measurements.

5. The system of claim 4, wherein the second characteristic is an end of the pressure waveform.

6. The system of claim 1, wherein the wave free period includes a time window between a peak pressure time ($t_{sub.Pmax}$) and an end of pressure waveform time ($t_{sub.Pend}$).

7. The system of claim 6, wherein the time window extends from $t_{sub.Pmax}+150$ ms to $t_{sub.Pend}-50$ ms.

8. The system of claim 6, wherein the time window is a mid-window between $t_{sub.Pmax}$ and $t_{sub.Pend}$.

9. The system of claim 8, wherein the time window is a mid $3/5$ window between $t_{sub.Pmax}$ and $t_{sub.Pend}$.

10. The system of claim 1, wherein the wave free period has a length of at least 100 ms.

11. The system of claim 1, wherein the wave free period has a predetermined duration.

12. The system of claim 1, wherein the wave free period corresponds to when a differential of flow velocity (dU) is minimal or absent.

13. The system of claim 1, wherein the wave free period corresponds to when a differential of flow velocity (dU) is below a threshold.

14. The system of claim 13, wherein the threshold of the differential of flow velocity (dU) is a predetermined deviation from zero.

15. The system of claim 14, wherein the predetermined deviation is $\pm 2 \times 10^{-4}$.

16. The system of claim 13, wherein the threshold of the differential of flow velocity (dU) is a percentage of a maximum differential of flow velocity ($dU_{sub.max}$).

17. The system of claim 13, wherein the threshold is 20% or less than a maximum differential of flow velocity ($dU_{sub.max}$).

18. The system of claim 1, wherein the at least one pressure-sensing probe comprises a pressure-sensing wire.

19. The system of claim 1, wherein the at least one pressure-sensing probe comprises a pressure transducer.

20. The system of claim 1, wherein the processor is in wired communication with the at least one pressure-sensing probe.

21. The system of claim 1, wherein the processor is in wireless communication with the at least one pressure-sensing probe.

22. The system of claim 1, wherein the processor is further configured to: identify the wave free period based on the received pressure measurements.

23. A method of assessing a narrowing in a blood vessel, the method comprising: receiving, with a processor in communication with at least one pressure-sensing probe, pressure measurements occurring during a cardiac cycle without hyperaemia obtained by the at least one pressure-sensing probe while the at least one pressure-sensing probe is positioned within the blood vessel; and calculating, with the processor, a pressure ratio using a subset of the pressure measurements occurring during a wave free period of the cardiac cycle, wherein the pressure ratio provides an assessment of a severity of the narrowing in the blood vessel.

24. The method of claim 23, wherein a start of the wave free period occurs after a first characteristic of a pressure waveform of the received pressure measurements.

25. The method of claim 24, wherein the first characteristic of the pressure waveform is a peak pressure.

26. The method of claim 24, wherein an end of the wave free period occurs before a second characteristic of the pressure waveform of the received pressure measurements.

27. The method of claim 26, wherein the second characteristic is an end of the pressure waveform.

28. The method of claim 23, wherein the wave free period includes a time window between a peak pressure time ($t_{sub.Pmax}$) and an end of pressure waveform time ($t_{sub.Pend}$).

29. The method of claim 28, wherein the time window extends from $t_{sub.Pmax}+150$ ms to

t.sub.Pend-50 ms.

30. The method of claim 28, wherein the time window is a mid-window between t.sub.Pmax and t.sub.Pend.

31. The method of claim 30, wherein the time window is a mid 3/5 window between t.sub.Pmax and t.sub.Pend.

32. The method of claim 23, wherein the wave free period has a length of at least 100 ms.

33. The method of claim 23, wherein the wave free period has a predetermined duration.

34. The method of claim 23, wherein the wave free period corresponds to when a differential of flow velocity (dU) is minimal or absent.

35. The method of claim 23, wherein the wave free period corresponds to when a differential of flow velocity (dU) is below a threshold.

36. The method of claim 35, wherein the threshold of the differential of flow velocity (dU) is a predetermined deviation from zero.

37. The method of claim 36, wherein the predetermined deviation is $\pm 2 \times 10^{-4}$.

38. The method of claim 35, wherein the threshold of the differential of flow velocity (dU) is a percentage of a maximum differential of flow velocity (dU.sub.max).

39. The method of claim 35, wherein the threshold is 20% or less than a maximum differential of flow velocity (dU.sub.max).

40. The method of claim 23, wherein the at least one pressure-sensing probe comprises a pressure-sensing wire.

41. The method of claim 23, wherein the at least one pressure-sensing probe comprises a pressure transducer.

42. The method of claim 23, wherein the processor is in wired communication with the at least one pressure-sensing probe.

43. The method of claim 23, wherein the processor is in wireless communication with the at least one pressure-sensing probe.

44. The method of claim 23, further comprising: identifying, with the processor, the wave free period based on the received pressure measurements.
